drug cards
Chapter 23
HYDANTOINS — CLASS MASTER DRUG CARD
Prototype: Phenytoin
Drugs: Phenytoin (Dilantin), fosphenytoin (Cerebyx/Sesquient).
Mechanism: Stabilize neuronal membranes by influencing ionic channels and decreasing repetitive abnormal firing.
Uses: Tonic-clonic and certain focal seizures; selected acute/neurosurgical seizure management.
Common adverse effects: Drowsiness, dizziness, confusion, fatigue, GI symptoms.
Signature toxicities: Nystagmus, ataxia, dysarthria, gingival hyperplasia, liver injury, marrow suppression and serious rash.
Precautions: Liver/renal dysfunction, pregnancy, older age, hypersensitivity and severe CNS depression.
Interactions: Other CNS depressants, interacting antiseizure medications, ginkgo and other supplements.
Nursing: Neurological assessment, fall precautions, gums/skin checks, CBC/organ monitoring and prescribed therapeutic concentrations.
Patient teaching: Consistent dosing, no abrupt discontinuation, dental care, interaction review and reportable danger signs.
⭐ Phenytoin — Prototype Card
Recognize: Dilantin · 10–20 mcg/mL total serum reference.
Best exam association: Tonic-clonic/focal seizures plus nystagmus, ataxia, slurred speech and gingival hyperplasia.
Distinctive PK: Hepatic metabolism, variable elimination.
Priority: New neurological impairment = assess for toxicity and protect from injury.
BARBITURATES — CLASS MASTER DRUG CARD
Prototype: Phenobarbital
Drugs: Phenobarbital (Luminal), primidone (Mysoline).
Mechanism: General CNS depression with enhanced inhibitory signaling and reduced neuronal excitability.
Uses: Generalized tonic-clonic and certain focal seizures; phenobarbital has selected acute convulsive indications.
Adverse effects: Somnolence, dizziness, confusion, GI symptoms, hypotension and bradycardia.
Serious toxicity: Respiratory depression, coma, withdrawal seizures and severe dermatological reactions.
Interactions: Alcohol and other CNS depressants; hepatic enzyme induction may decrease effects of susceptible drugs such as warfarin.
Precautions: Organ dysfunction, respiratory disease, pregnancy, older age and dependence.
Nursing: Monitor ventilation, consciousness, hemodynamics, seizure control, drug exposure and interactions.
Teaching: Consistent medication use, no abrupt withdrawal, avoid alcohol and unapproved CNS depressants.
Phenobarbital — Prototype Card
Signature: Long-acting CNS depressant and antiseizure drug.
Half-life: Approximately 79 hours.
Serum reference: 10–40 mcg/mL.
Exam hitters: Respiratory depression, enzyme induction, prolonged sedation, physical dependence and withdrawal seizures.
Benzodiazepines — Class Master Card
Prototype: Diazepam
Drugs: Diazepam, clonazepam, clobazam.
Mechanism: Potentiate GABA-mediated neuronal inhibition.
Uses: Selected acute, intermittent, or adjunctive seizure treatment.
Common adverse effects: Sedation, fatigue, dizziness, confusion, impaired coordination.
Serious risks: Respiratory depression with interacting depressants, dependence, withdrawal seizures.
PK: GI absorption, hepatic metabolism, urinary excretion; relatively long half-lives in this group.
Nursing: Assess ABCs, seizure response, sedation, cardiovascular status, and drug combinations.
Teaching: Avoid alcohol and unapproved depressants; maintain consistent prescribed therapy; never abruptly discontinue long-term use.
Drug card | Distinctive exam fact |
|---|---|
Diazepam — prototype | Acute/intermittent convulsive treatment, GABA enhancement, long half-life, respiratory monitoring |
Clonazepam | Selected seizures; effectiveness may decline over time |
Clobazam | Adjunct for Lennox–Gastaut-associated seizures |
Succinimides — Class Master Card
Prototype: Ethosuximide
Drugs: Ethosuximide, methsuximide.
Use: Absence seizures.
Mechanism: Suppress absence-associated abnormal electrical activity.
Adverse effects: Drowsiness, dizziness, GI disturbance, ataxia.
Serious risks: Bone marrow suppression, pancytopenia, SJS, mood changes.
PK: Hepatic metabolism, renal elimination; ethosuximide half-life varies by age.
Interactions: May decrease primidone concentrations.
Nursing: Monitor seizures, CBC when indicated, mood, skin, and infection/bleeding signs.
Teaching: Consistent dosing and prompt reporting of serious symptoms.
Drug card | Distinctive fact |
|---|---|
Ethosuximide — prototype | First-choice recognition for typical absence seizures; 40–100 mcg/mL |
Methsuximide | Alternative for refractory absence seizures; greater adverse-effect concerns |
GABA-Modulating Agents — Class Master Card
Prototype: Valproic acid
Drugs: Valproic acid, divalproex sodium, zonisamide, acetazolamide.
Mechanisms: Valproate reduces abnormal electrical activity and may increase GABA activity. Zonisamide acts on voltage-sensitive sodium/calcium channels; acetazolamide changes electrolyte movement.
Uses: Seizure treatment, with valproate also used for mania and migraine prevention.
Common effects: CNS and GI disturbances, dizziness, fatigue.
Serious risks: Valproate-related liver injury, pancreatitis, thrombocytopenia, hyperammonemia, DRESS, fetal harm.
Interactions: Multiple antiseizure drug combinations; drug-specific interactions with other medications.
Nursing: Monitor seizure response, neurological condition, CBC/platelets, liver function and serious symptom patterns.
Teaching: Consistent dosing, no unsupervised abrupt discontinuation, report significant bleeding, abdominal pain, jaundice, confusion or rash.
⭐ Valproic Acid — Prototype Card
Must Know
Key indication: Myoclonic seizures; also absence and certain focal seizures, mania and migraine prevention.
Action: Reduces abnormal electrical activity; may increase GABA effects.
Roadmap serum reference: Commonly 50–100 mcg/mL for epilepsy, depending on indication and laboratory.
Half-life: Approximately 9–16 hours.
Top toxicities: Liver injury, pancreatitis, thrombocytopenia, hyperammonemia.
Important interaction: Phenytoin/phenobarbital and other antiseizure medications.
Priority nursing judgment: Severe abdominal pain, significant confusion, jaundice, or unusual bleeding requires prompt evaluation.
Chapter 24-
Master Class Card — Dopamine Precursors
Levodopa + Carbidopa
Must know
Prototype: Carbidopa-levodopa (Sinemet)
CLASS / PURPOSE
Dopamine precursor with peripheral DOPA decarboxylase inhibitor. Improves dopamine signaling in the basal ganglia to reduce motor manifestations of Parkinson's disease.
MOA
Levodopa crosses the BBB and converts to dopamine in the CNS.
Carbidopa inhibits peripheral conversion of levodopa, increasing CNS delivery and reducing peripheral adverse effects.
MUST KNOW: Levodopa crosses the BBB; dopamine itself does not. Carbidopa prevents peripheral levodopa conversion.
INDICATIONS
Parkinson's disease and appropriate parkinsonian syndromes; improves bradykinesia, rigidity, tremor, and motor functioning.
PK / PD
Oral medication; affected by absorption and dietary interactions. Prototype summary gives a half-life of approximately two hours. Clinical response and adverse effects guide monitoring rather than a routine serum therapeutic range.
COMMON ADVERSE EFFECTS
Nausea, vomiting, dizziness, fatigue, weakness, changes in sweating, GI disturbances.
SERIOUS COMPLICATIONS
Dyskinesia, hallucinations/psychosis, orthostatic hypotension, clinically important cardiac abnormalities.
CONTRAINDICATIONS / CAUTIONS
Allergy, angle-closure glaucoma, recent nonselective MAOI use; important cautions include cardiac disease, psychosis, melanoma history, renal/hepatic dysfunction, urinary obstruction, and pregnancy/lactation.
INTERACTIONS
Iron salts may decrease effectiveness; high-protein meals may reduce response; dopamine antagonists oppose therapeutic effects; nonselective MAOIs may cause dangerous interactions.
THERAPEUTIC RANGE
No routinely established serum therapeutic range.
ANTIDOTE
No specific routinely used antidote; manage adverse reactions through urgent assessment, supportive care, and appropriate medication adjustment.
NURSING ASSESSMENT
Motor function, timing of doses, BP/orthostatics, HR, mental status, swallowing, elimination, drug/supplement history, relevant labs and skin findings.
NURSING ACTIONS / HOLD OR ESCALATE
Administer on schedule when safe. Do not independently increase or double doses. Escalate severe hypotension, syncope, hallucinations with safety concerns, significant dyskinesia, arrhythmia symptoms, or unsafe swallowing. Verify any necessary medication changes with the prescriber.
PATIENT EDUCATION
Consistent dosing, report interactions and new symptoms, follow an individualized food/medication plan, move slowly when standing, maintain fall precautions, and attend regular follow-up.
CLASS CONNECTION
MAO-B and COMT inhibitors can later be used to preserve dopamine activity or extend levodopa effectiveness.
Drug-Specific Card 1 — Levodopa
Levodopa (L-DOPA)
Dopamine precursor · Also listed in the chapter as inhaled levodopa (Inbrija)
Unique mechanism: Direct biochemical precursor converted into dopamine after reaching the CNS.
MUST KNOW: Levodopa crosses the blood-brain barrier and is converted into dopamine.
Major limitation when used without carbidopa: More peripheral levodopa conversion, less levodopa reaching the brain, and more peripheral adverse effects.
Key clinical facts: Symptomatic relief, fluctuating motor response, interactions with iron and dietary factors, and dopaminergic adverse effects.
Drug-specific distinction: Inhaled levodopa (Inbrija) has a different administration route from oral combination formulations. Route and product must be verified; they are not freely interchangeable.
Nursing reasoning: The nurse must understand both where levodopa needs to act and which factors prevent it from reaching that site.
Drug-Specific Card 2 — Carbidopa-Levodopa (Sinemet)
Carbidopa + Levodopa
Combination prototype · Examples also include extended-release formulations such as Rytary
Unique mechanism: Peripheral decarboxylase inhibition plus CNS dopamine replacement.
MUST KNOW: Carbidopa improves levodopa availability in the CNS while reducing peripheral dopamine production.
Why the combination is preferred: Better delivery of levodopa to its intended therapeutic site and fewer peripheral adverse effects than levodopa alone.
Major adverse effects: Nausea, orthostatic hypotension, dyskinesia, hallucinations, cardiac changes.
Key interactions: Iron supplements, high-protein meals, dopamine antagonists, MAOIs.
MUST KNOW: Give on the prescribed schedule. Determine whether returning symptoms are related to missed doses, interactions, wearing-off, or disease progression.
Formulation safety: Immediate-release and extended-release products differ in administration characteristics. Verify the specific product and do not crush an extended-release formulation without authoritative confirmation.
Nursing focus: Functional improvement, dose-response timing, adverse-effect monitoring, fall prevention, and adherence.